Index

Note: Page numbers of article titles are in boldface type.

A
Acetaminophen
  ALF due to, 576–577
  described, 587–588
  hepatotoxicity of, 588–590
  pharmacology of, 588–590
Acetaminophen-protein adducts
  in acetaminophen-related DILI, 598
Acetaminophen-related DILI, 587–607
  clinical manifestations of, 593–594
  described, 588–590
  diagnosis of
    tools in, 594–598
    epidemiology of, 588
    factors influencing, 590–592
    general approach to, 594–598
    introduction, 587–588
  management of, 598–600
    gastrointestinal decontamination in, 598
    liver transplantation in, 600
    NAC in, 598–600
  pharmacology related to, 588–590
Acetic acid derivatives
  hepatotoxicity of
    characteristics of, 648–650
Acetylsalicylic acid (aspirin)
  hepatotoxicity of
    characteristics of, 651
Acidosis
  lactic
    NRTIs and, 658
Actinomycin
  hepatotoxicity of, 677
Acute liver failure (ALF)
  background of, 575–576
  drug-induced, 520, 575–586
    acetaminophen-related, 576–577
    AEDs–related
      outcomes of, 694–695
      background of, 575–576
      future directions in, 583–584
      genomics in, 583–584

http://dx.doi.org/10.1016/S1089-3261(13)00083-4
1089-3261/13/$ – see front matter © 2013 Elsevier Inc. All rights reserved.
Acute (continued)
   management of, 579–582
   corticosteroids in, 582
   hepatic encephalopathy related to, 582
   NAC in, 580–581
   transplantation in, 582–583
   prognosis of, 582–583
   statins-related, 707–708
Adaptive immunity
   in DILI, 513–515
Adenoma(s)
   hepatocellular
   DILI and, 558
AEDs. See Antiepileptic drugs (AEDs)
Age
   acetaminophen-related DILI associated with, 592
Alcohol
   acetaminophen-related DILI associated with, 591
ALF. See Acute liver failure (ALF)
Alkylating agents
   hepatotoxicity of, 676–676
Aloe vera
   hepatotoxicity of, 724
Amiodarone
   macrovesicular steatosis and steatohepatitis due to, 539–540
Anthelmintic agents
   hepatotoxicity of, 627
Antibiotic(s)
   antitumor
      hepatotoxicity of, 677–678
   in cirrhosis, 627–629
   hepatotoxicity of, 609–642
      anthelmintic agents, 627
      antifungal agents, 626–627
      antiprotozoal agents, 627
      antiviral agents, 627
      ATDs, 621–626. See also Antituberculous drugs (ATDs), hepatotoxicity of
      biomarkers in, 616
      cephalosporins, 617
      chloramphenicol, 620–621
      fluoroquinolones, 618
      incidence of, 610–614
      infections causing jaundice, 614–616
      introduction, 609–610
      macrolides, 619–620
      nitrofurantoin, 620
      penicillins, 616–617
      pharmacogenomics in, 616
      sulfonamides, 618–619
      tetracyclines, 619
Antibody(ies)
monoclonal
  hepatotoxicity of, 681
Antiepileptic drugs (AEDs)
  described, 688
  hepatotoxicity of, 687–697
    ALF due to
      outcomes of, 694–695
      background of, 687–688
      CBZ, 692–693
      felbamate, 694
      lamotrigine, 693
      PB, 693–694
      PHT, 691–692
      VPA, 688–690
Antifungal agents
  hepatotoxicity of, 626–627
Antimetabolites
  hepatotoxicity of, 673–676
    azathioprine, 673
    capecitabine, 673, 675
    cytarabine/cytosine arabinoside, 675
    5-FU, 675
    5-FUdr, 675–676
    gemcitabine, 676
    methotrexate, 676
    6-MP, 676
    thioguanine/tioguan/thioguanine/6-thioguanine, 676
Antiprotozoal agents
  hepatotoxicity of, 627
Antiretroviral (ARV)-associated liver disease, 657–661
  described, 657–658
  NNRTIs and, 659–661
  NRTIs and, 658–659
  in patients coinfected with HIV and HCV, 661–665
    described, 661–662
    treatment of
      future directions in, 664
      interactions with ARVs, 662–664
      reasons for, 662
Antituberculous drugs (ATDs)
  after liver injury
    reintroduction of, 624
  hepatotoxicity of, 621–626
    isoniazid, 621–622
    monitoring for, 623–624
    PAS, 623
    prevention of, 625
    pyrazinamide, 622–623
    rifampin, 622
    risk factors for, 624
    pharmacogenomics of, 624
Antitumor antibiotics  
  hepatotoxicity of, 677–678
Antiviral agents  
  hepatotoxicity of, 627
Apoptosis  
  in DILI, 508
Arsenic trioxide  
  hepatotoxicity of, 681
ARV. See Antiretroviral (ARV)
Asparaginase  
  hepatotoxicity of, 681
Aspirin  
  microvesicular steatosis due to, 537–538
ATDs. See Antituberculous drugs (ATDs)
Azathioprine  
  hepatotoxicity of, 673

B
Benoxaprofen  
  hepatotoxicity of, 645–646
Bevacizumab  
  hepatotoxicity of, 681
Bile acid sequestrants  
  hepatotoxicity of, 709
Biomarker(s)  
  in antibiotic DILI, 616
Black cohosh  
  hepatotoxicity of, 725
Bleomycin  
  hepatotoxicity of, 677
Body and muscle building supplements  
  hepatotoxicity of, 722–723
Bortezomib  
  hepatotoxicity of, 681–682
Bromfenac  
  hepatotoxicity of, 645–646
Busulfan  
  hepatotoxicity of, 676

C
Cabazitaxel  
  hepatotoxicity of, 678
Capecitabine  
  hepatotoxicity of, 673, 675
Carbamazepine (CBZ)  
  hepatotoxicity of, 692–693
Carboplatin  
  hepatotoxicity of, 679
Carmustine  
  hepatotoxicity of, 678
CBZ. See Carbamazepine (CBZ)
CCR5 antagonists
liver disease associated with, 660
Celecoxib
hepatotoxicity of, 651
Cell death
types of, 508
Cephalosporins
hepatotoxicity of, 617
Chaparral
hepatotoxicity of, 724
Chemotherapy agents
hepatotoxicity of, 671–686. See also specific drugs
alkylating agents, 676–676
antimetabolites, 673–676
antitumor antibiotics, 677–678
arsenic trioxide, 681
asparaginase, 681
bortezomib, 681–682
clinical presentation of, 673
criteria for, 671–673
hydroxyurea, 682
immunotherapy-related, 681
introduction, 671–673
kinase inhibitors, 680
mammalian target of rapamycin inhibitors, 680–681
mechanism of injury, 673
monoclonal antibodies, 681
nitrosureas, 678
platinum derivatives, 679–680
procarbazine, 682
risk factors for, 673
taxanes, 678–679
topoisomerase inhibitors, 679
vinca alkaloids, 679
macroversicular steatosis due to, 540–541
steatohepatitis due to, 540–541
Chlorambucil
hepatotoxicity of, 677
Chloramphenicol
hepatotoxicity of, 620–621
Cholestasis
defined, 519
drug-induced, 519–531
acute cholestatic DILI, 522–526
clinical features of, 525
described, 522–525
management of, 525
pathology of, 526
causes of
evaluation of, 521–522
Cholestasis (continued)
  chronic cholestatic DILI, 526–528
  clinical features of, 527
  described, 526–527
  management of, 527–528
  pathology of, 527
  prognosis of, 528
  classification of, 520, 522
  epidemiology of, 520
  pathogenesis of, 521
  prognosis of, 528
  risk factors for, 520–521
Cholestatic injury pattern
  in DILI, 551–552
Chronic liver disease
  acetaminophen-related DILI associated with, 592
  statins in patients with, 706–708
Cirrhosis
  antibiotic use in, 627–629
  DILI in patients with
    medications causing, 738–740
    statins in patients with, 707
Cisplatin
  hepatotoxicity of, 679
Cocaine
  microvesicular steatosis due to, 538
Comfrey
  hepatotoxicity of, 725
Conjugated linoleic acid
  hepatotoxicity of, 723
Corticosteroid(s)
  in drug-induced ALF management, 582
  NAFLD worsening due to, 541
COX-2 inhibitors. See Cyclooxygenase-2 (COX-2) inhibitors
Cyclooxygenase-2 (COX-2) inhibitors
  hepatotoxicity of, 650–651
Cyclophosphamide
  hepatotoxicity of, 677
Cytarabine/cytosine arabinoside
  hepatotoxicity of, 675
Cytoplasmic illusions, lipidosis, and pigments
  DILI and, 555–558

D
Dacarbazine
  hepatotoxicity of, 677
Diclofenac
  hepatotoxicity of, 648–650
Diethyramioethoxyhexestrol and perhexiline maleate
  macrovesicular steatosis and steatohepatitis due to, 540
DILI. See Drug-induced liver injury (DILI)

Doxorubicin
  hepatotoxicity of, 678

Drug development and approval
  final stages of
    hepatotoxicity of, 749–767. See also Drug-induced liver injury (DILI), at final stages of drug development and approval

Drug-induced acute liver failure (ALF). See Acute liver failure (ALF), drug-induced

Drug-induced hepatotoxicity. See Drug-induced liver injury (DILI)

Drug-induced lived injury (DILI)
  at final stages of drug development and approval, 749–767
    causality assessment for, 758–764
    described, 758–759
    methods in, 759–762
    hepatic discontinuation rules, 757–758
    hepatic safety data in
      organization and analysis of, 755–757
      historical perspective on, 750–752
      introduction, 749–750
      signals of, 752–755
        ALT increase vs. Hy’s law, 754–755
        hepatic injury vs. adaptation, 752–754

Drug-induced liver injury (DILI), 565–573
  acetaminophen-related, 587–607. See also Acetaminophen-related DILI
  AEDs–related, 687–697. See also Antiepileptic drugs (AEDs), hepatotoxicity of
  ALF related to, 520
  antibiotic-related, 609–642. See also Antimicrobial(s), hepatotoxicity of
  ATDs–associated
    monitoring for, 623–624
  chemotherapy agents–related, 671–686. See also Chemotherapy agents, hepatotoxicity of
  cholestatic, 519–531. See also Cholestasis, drug-induced
    in cirrhosis patients
      medications causing, 738–740
    clinical patterns of, 519, 644
    clinical resources for, 645
    defined, 566
    described, 507–508, 519, 547–548, 687–688
    diagnosis of, 567–568, 644
    epidemiology of, 565–566
    fundamental process in, 508
  HDSs–related, 715–735. See also Herbal and dietary supplements (HDSs)
  histopathologic manifestations of, 547–564
    cholestatic injury pattern, 551–552
    cytoplasmic illusions, lipidosis, and pigments, 555–558
    granuloma, 553–555
    granulomatous hepatitis, 553–555
    HCA, 558
    hepatocellular injury pattern, 548–551
      in acute injury, 548
Drug-induced (continued)
   in chronic injury, 550–551
      confluent and zonal necrosis, 549–550
      spotty cell death, 548–549
   introduction, 547–548
      steatosis and steatohepatitis pattern, 552–553
   vascular injury patterns, 555
Hy's law and severity of, 644–645
   idiosyncratic, 577–578
      defined, 644
   incidence of, 507
lipid-lowering agents–related, 699–714. See also Lipid-lowering agents, hepatotoxicity of
   liver transplantation–related, 737–747. See also Liver transplantation, hepatotoxicity
   and drug interactions in candidates and recipients of
mechanisms of, 507–518
   adaptive immunity, 513–515
   apoptosis, 508
   innate immunity, 513–515
   mitochondrial adaptation, 512–513
   mitochondrial dysfunction, 510–512
   necroptosis, 508
   necrosis, 508
   reactive metabolites, 508–509
   stress signaling, 509–510
NSAIDs–related, 643–656. See also Nonsteroidal antiinflammatory drugs (NSAIDs),
   hepatotoxicity of
   severity of
      Hy's law and, 644–645
steatohepatitis, 533–546. See also Steatohepatitis, drug-induced
terminology related to, 566–567
treatment of, 565–573

E
Encephalopathy
   hepatic
      drug-induced
         ALF management related to, 582
Enfuvirtide
   liver disease associated with, 661
Enolic acid derivatives
   hepatotoxicity of, 650
Ephedra
   hepatotoxicity of, 723
Eribulin
   hepatotoxicity of, 678–679
Erlotinib
   hepatotoxicity of, 680
Etoposide/VP-16
   hepatotoxicity of, 679
Everolimus
hepatotoxicity of, 680
Ezetimibe
  hepatotoxicity of, 708–709

F
Felbamate
  hepatotoxicity of, 694
Fibrates
  hepatotoxicity of, 710–711
5-FU. See Fluouracil (5-FU)
5-FUdr. See Fluorodeoxyuridine (5-FUdr)
Flavocoxid
  hepatotoxicity of, 724
Fluconazole
  hepatotoxicity of, 626
Fluocytosine
  hepatotoxicity of, 627
Fluorodeoxyuridine (5-FUdr)
  hepatotoxicity of, 675–676
Fluoroquinolones
  hepatotoxicity of, 618
Fluouracil (5-FU)
  hepatotoxicity of, 675
Fusion inhibitor
  liver disease associated with, 661

G
Gastrointestinal complaints
  supplements for
    hepatotoxicity of, 724
Gastrointestinal decontamination
  in acetaminophen-related DILI management, 598
Gefitinib
  hepatotoxicity of, 680
Gemcitabine
  hepatotoxicity of, 676
Genetics
  acetaminophen-related DILI associated with, 592
Genomics
  in drug-induced ALF, 583–584
Germander
  hepatotoxicity of, 723
Granuloma
  DILI and, 553–555
Granulomatous hepatitis
  DILI and, 553–555
Great celandine
  hepatotoxicity of, 724
Green tea
  hepatotoxicity of, 723
HCA. See Hepatocellular adenoma (HCA)
HCV. See Hepatitis C virus (HCV)
HDSs. See Herbal and dietary supplements (HDSs)
Hepatic discontinuation rules
during drug development, 757–758
Hepatic encephalopathy
drug-induced ALF management related to, 582
Hepatic steatosis
defined, 533
NRTIs and, 658
Hepatic venoocclusive disease (VOD)
DILI and, 555
Hepatitis
granulomatous
DILI and, 553–555
peliosis
DILI and, 555
Hepatitis C virus (HCV)
HIV with
hepatotoxicity of ARV therapy in patients with, 661–665. See also Antiretroviral (ARV)-associated liver disease, in patients coinfected with HIV and HCV
statins and, 706–707
Hepatocellular adenoma (HCA)
DILI and, 558
Hepatocellular injury pattern
in DILI, 548–551. See also Drug-induced liver injury (DILI), histopathologic manifestations of, hepatocellular injury pattern
Hepatotoxicity
drug-induced. See also specific types, agents, and Drug-induced liver injury (DILI)
Herbal and dietary supplements (HDSs)
hepatotoxicity of, 715–735
adulteration associated with, 721
body and muscle building supplements, 722–723
causality assessment related to, 719–721
contamination related to, 721
diagnosis of, 718–719
epidemiology of, 716–717
future directions in, 726–727
gastrointestinal complaints supplements, 724
introduction, 715–716
joint health supplements, 724
noni, 726
pain relief supplements, 725
pennyroyal, 726
psychotropic effects–related supplements, 725–726
traditional remedies, 726
weight loss supplements, 723–724
regulatory environment for, 717–718
Herbalife
hepatotoxicity of, 723

Herbs

acetaminophen-related DILI associated with, 591–592
HIV. See Human immunodeficiency virus (HIV)

Human immunodeficiency virus (HIV)

HCV with

hepatotoxicity of ARV therapy in patients with, 661–665. See also Antiretroviral (ARV)-associated liver disease, in patients coinfected with HIV and HCV

Hydroxycut

hepatotoxicity of, 724

Hydroxyurea

hepatotoxicity of, 682

Hypertension

portal

noncirrhotic

NRTIs and, 659

Hy’s law

severity of DILI and, 644–645

I

Ibuprofen

hepatotoxicity of, 648

Idiosyncratic drug-related liver injury, 577–578, 644

Ifosfamide

hepatotoxicity of, 677

Imatinib

hepatotoxicity of, 680

Immunity

adaptive

in DILI, 513–515

innate

in DILI, 513–515

Immunotherapy agents

hepatotoxicity of, 681

Infection(s). See also specific types

jaundice due to

antimicrobial-related, 614–616

Innate immunity

in DILI, 513–515

Integrase inhibitors

liver disease associated with, 661

Interleukin 2

hepatotoxicity of, 681

Isoniazid

hepatotoxicity of, 621–622

J

Jaundice

antimicrobial-related infections causing, 614–616
Joint health supplements
hepatotoxicity of, 724

K
Kava kava
hepatotoxicity of, 725
Ketoconazole
hepatotoxicity of, 626
Kinase inhibitors
hepatotoxicity of, 680

L
Lactic acidosis
NRTIs and, 658
Lamotrigine
hepatotoxicity of, 693
Lipid-lowering agents
hepatotoxicity of, 699–714. See also specific agents
bile acid sequestrants, 709
ezetimibe, 708–709
fibrates, 710–711
introduction, 699–700
niacin, 709–710
statins, 700–708
Liver disease(s)
ARV-associated, 657–661. See also Antiretroviral (ARV)-associated liver disease
chronic
acetaminophen-related DILI associated with, 592
statins in patients with, 706–708
nonalcoholic fatty. See Nonalcoholic fatty liver disease (NAFLD)
Liver failure
acute. See Acute liver failure (ALF)
Liver injury
drug-induced. See Drug-induced liver injury (DILI)
Liver transplantation
in acetaminophen-related DILI management, 600
in drug-induced ALF management, 582–583
hepatotoxicity and drug interactions in candidates and recipients of, 737–747
cirrhosis-related, 738–740
discussion, 742–743
introduction, 737–738
post-transplantation–related, 740–742
latent TB and, 626
statins in recipients of, 707
Lumiracoxib
hepatotoxicity of, 645–646

M
Macrolides
hepatotoxicity of, 619–620
Macrovesicular steatosis
  in DILI, 553
drugs causing, 539–541
Medication(s)
  acetaminophen-related DILI associated with, 591–592
Melphalan
  hepatotoxicity of, 677
6-Mercaptopurine (6-MP)
  hepatotoxicity of, 676
Metabolite(s)
  reactive
    in DILI, 508–509
Methotrexate
  hepatotoxicity of, 676
  NAFLD worsening due to, 541
Microvesicular steatosis
  in DILI, 553
drugs causing, 537–539
Mitochondrial adaptation
  in DILI, 512–513
Mitochondrial dysfunction
  in DILI, 510–512
Mitomycin
  hepatotoxicity of, 678
Monoclonal antibodies
  hepatotoxicity of, 681
6-MP. See 6-Mercaptopurine (6-MP)

N

N-acetylcysteine (NAC)
  in acetaminophen-related DILI management, 598–600
  in ALF, 580–581
NAC. See N-acetylcysteine (NAC)
NAFLD. See Nonalcoholic fatty liver disease (NAFLD)
Naproxen
  hepatotoxicity of, 648
NASH. See Nonalcoholic steatohepatitis (NASH)
NCPH. See Noncirrhotic portal hypertension (NCPH)
Necroptosis
  in DILI, 508
Necrosis
  in DILI, 508
Niacin
  hepatotoxicity of, 709–710
Nimesulide
  hepatotoxicity of, 646–647
Nitrofurantoin
  hepatotoxicity of, 620
Nitrosoareas
  hepatotoxicity of, 678
NNRTIs. See Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  liver disease associated with, 659–661
    CCR5 antagonists, 660
    described, 659–660
    fusion inhibitor, 661
    integrase inhibitors, 661
    protease inhibitors, 660

Nonalcoholic fatty liver disease (NAFLD)
  defined, 533–534
  underlying
    drugs leading to worsening of, 541
Nonalcoholic steatohepatitis (NASH)
  statins and, 707

Noncirrhotic portal hypertension (NCPH)
  NRTIs and, 659
Noni
  hepatotoxicity of, 726

Nonsteroidal antiinflammatory drugs (NSAIDs)
  hepatotoxicity of, 643–656
    benoxaprofen, 645–646
    bromfenac, 645–646
    characteristics of, 648–651
    epidemiology of, 647
    introduction, 643–644
    lumiracoxib, 645–646
    nimesulide, 646–647
  microvesicular steatosis due to, 539

NRH
  DILI and, 555

NSAIDs. See Nonsteroidal antiinflammatory drugs (NSAIDs)

Nucleoside reverse transcriptase inhibitors (NRTIs)
  liver disease associated with, 658–659
    hepatic steatosis, 658
    lactic acidosis, 658
    NCPH, 659
  microvesicular steatosis due to, 539

Nutritional status
  acetaminophen-related DILI associated with, 592

O

Obliterative portal venopathy (OPV)
  DILI and, 555
OPV. See Obliterative portal venopathy (OPV)

Oxaliplatin
  hepatotoxicity of, 679–680

Paclitaxel
  hepatotoxicity of, 678
Pain relief
  supplements for
    hepatotoxicity of, 725
Para-aminosalicylic acid (PAS)
  hepatotoxicity of, 623
PAS. See Para-aminosalicylic acid (PAS)
Pazopanib
  hepatotoxicity of, 680
PB. See Phenobarbital (PB)
Pegylated interferon α
  hepatotoxicity of, 681
Peliosis hepatitis
  DILI and, 555
Penicillins
  hepatotoxicity of, 616–617
Pennyroyal
  hepatotoxicity of, 726
Phenobarbital (PB)
  hepatotoxicity of, 693–694
Phenytoin (PHT)
  hepatotoxicity of, 691–692
PHT. See Phenytoin (PHT)
Piroxicam
  hepatotoxicity of, 650
Platinum derivatives
  hepatotoxicity of, 679–680
Portal hypertension
  noncirrhotic
    NRTIs and, 659
Pregnancy
  acetaminophen-related DILI associated with, 592
Procarbazine
  hepatotoxicity of, 682
Propionic acid derivatives
  hepatotoxicity of, 648
Protease inhibitors
  liver disease associated with, 660
Psychotropic effects
  supplements for
    hepatotoxicity of, 725–726
Pyrazinamide
  hepatotoxicity of, 622–623

R
Rapamycin inhibitors
  mammalian target of
    hepatotoxicity of, 680–681
Regorafenib
  hepatotoxicity of, 680
Rifampin
  hepatotoxicity of, 622
Salicylate(s)
  hepatotoxicity of, 651
Sinusoidal dilatation
  peliosis hepatitis and
    in DILI, 555
Sinusoidal obstruction syndrome (SOS)
  DILI and, 555
Skullcap
  hepatotoxicity of, 725
 Sorafenib
  hepatotoxicity of, 680
Statin(s)
  in chronic liver disease patients, 706–708
    dosage of, 705
    drug interactions with, 706
    HCV and, 706–707
    hepatic function testing in patients taking, 705–706
    hepatotoxicity of, 700–708
      described, 700–704
      hydrophilicity of, 704–705
Steatohepatitis
  chemotherapy-associated, 540–541
  drug-induced, 533–546
    diagnosis of, 534–535
    drugs causing, 539–541
    management of, 541–542
    pathogenesis of, 535–537
      hepatic steatosis mechanisms in, 536–537
      mitochondrial structure in, 535–536
      steatohepatitis mechanisms in, 537
    pathologic spectrum of, 537–541
    pattern of, 552–553
    macrovesicular
      in DILI, 553
    mechanisms of, 537
    microvesicular
      in DILI, 553
    nonalcoholic
      statins and, 707
Steatosis
  drug-induced
    pathologic spectrum of, 537–541
    pattern of, 552–553
  hepatic
    defined, 533
    NRTIs and, 658
  macrovesicular
    in DILI, 553
    drugs causing, 539–541
microvesicular
  in DILI, 553
drugs causing, 537–539
Streptozotocin
  hepatotoxicity of, 678
Stress signaling
  in DILI, 509–510
Sulfonamides
  hepatotoxicity of, 618–619
Sulindac
  hepatotoxicity of
  characteristics of, 650

T
Tamoxifen
  NAFLD worsening due to, 541
Taxanes
  hepatotoxicity of, 678–679
TB. See Tuberculosis (TB)
Temsirolimus
  hepatotoxicity of, 680–681
Terbinafine
  hepatotoxicity of, 627
Tetracyclines
  hepatotoxicity of, 619
  microvesicular steatosis due to, 539
Thioguanine/tioguan/thioguanine/6-thioguanine
  hepatotoxicity of, 676
Topoisomerase inhibitors
  hepatotoxicity of, 679
Topotecan
  hepatotoxicity of, 679
Trastuzumab
  hepatotoxicity of, 681
Tuberculosis (TB)
  latent
    liver transplantation and, 626

U
Usnic acid
  hepatotoxicity of, 724

V
Valerian
  hepatotoxicity of, 725–726
Valproic acid (VPA)
  hepatotoxicity of, 688–690
  microvesicular steatosis due to, 539
Vascular injury patterns
  in DILI, 555
Venoocclusive disease (VOD)
  hepatic
    DILI and, 555
Vinca alkaloids
  hepatotoxicity of, 679
Vincristine
  hepatotoxicity of, 679
Vinorelbine
  hepatotoxicity of, 679
VOD. See Venoocclusive disease (VOD)
Voriconazole
  hepatotoxicity of, 626
VPA. See Valproic acid (VPA)

W
Weight loss supplements
  hepatotoxicity of, 723–724